Caribou Biosciences, Inc. ( (CRBU) ) has released its Q2 earnings. Here is a breakdown of the information Caribou Biosciences, Inc. presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Caribou Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing transformative therapies using CRISPR genome-editing technology, primarily in the field of allogeneic CAR-T cell therapies for hematologic malignancies. In its latest earnings report, Caribou Biosciences reported a net loss of $54.1 million for the second quarter of 2025, compared to a net loss of $37.7 million in the same period in 2024. The company’s revenue from licensing and collaboration decreased to $2.7 million from $3.5 million year-over-year, while operating expenses increased due to impairment charges and ongoing research and development efforts. Despite the financial challenges, Caribou Biosciences continues to advance its clinical-stage therapies and maintains a cash position of $25.2 million, with marketable securities valued at $158.7 million. Looking ahead, the company aims to leverage its CRISPR technology to achieve regulatory approval and commercialization of its product candidates, while managing its financial resources to support ongoing operations.